John Montgomery Yost, MD, MPH is a Clinical Associate Professor in Dermatology at Stanford Health Care and the Director of the Nail Disorders Clinic. After attending medical school at the University of Michigan, he completed his residency at the Ronald O. Perelman Department of Dermatology at New York University Langone Medical Center. His clinical and research interests include nail disorders, tumors of the nail apparatus, nail surgery, longitudinal melanonychia, brittle nail disease, and inflammatory nail disorders.
- Nail Disorders
- Nail Surgery
- Longitudinal Melanonychia
- Tumors of the Nail Apparatus
Clinical Associate Professor, Dermatology
Honors & Awards
Fulbright Scholar - Hamburg, Germany, United States Department of State, Bureau of Educational and Cultural Affairs
National Medical Honor Society, Alpha Omega Alpha (2009-Present)
Morris Leider Award for Excellence in Dermatology, New York University Langone Medical Center The Ronald O. Perelman Department of Dermatology (2014)
Boards, Advisory Committees, Professional Organizations
Member, Council for Nail Disorders (2013 - Present)
Residency: New York University Dermatology Residency NY
Board Certification: American Board of Dermatology, Dermatology (2014)
Medical Education: University of Michigan Medical School (2010) MI
Internship: Oakwood Hospital and Medical Center MI
Masters in Public Health, Boston University School of Public Health, Epidemiology
BA, Bowdoin College, Summa cum laude
Hidradenitis Suppurativa in Sexual and Gender Minorities: A Review and Considerations for Providers.
Journal of the American Academy of Dermatology
The literature on hidradenitis suppurativa (HS) in sexual and gender minorities (SGM) remains sparse. This review article aims to discuss critical factors for providers to consider in LGBTQIA patients with HS, including associated comorbidities, gender-affirming hormonal therapy, squamous cell carcinoma, infections in HIV-positive patients, and creating a welcoming clinic for SGM patients.
View details for DOI 10.1016/j.jaad.2022.03.008
View details for PubMedID 35283243
- Pernio-like eruption associated with COVID-19 in skin of color. JAAD case reports 2020; 6 (9): 892–97
Planimetric Post-hoc Analysis of Women With Onychomycosis from Tavaborole 5% Phase III Studies: Evidence of Greater Improvements in Patients With > 50% Baseline Infection
JOURNAL OF DRUGS IN DERMATOLOGY
2018; 17 (2): 168–72
Women with onychomycosis may suffer more effects on their quality of life than men. There is limited female-specific data on the treatment of onychomycosis. Tavaborole is a topical treatment option for onychomycosis. This post-hoc study evaluated the nail plates of women using data from the tavaborole 5% Phase III studies at baseline and end of study for the areas of healthy nail and infected nail. Over 52 weeks (48-week treatment, 4-week follow up), women treated with tavaborole had an average 32% increase in healthy nail and 21% decrease in infected nail. Patients with baseline infection involving >50% of the nail plate had an average increase in percentage of unaffected nail surface area of 81% and a corresponding 51% decrease in infected nail. These analyses suggest that patients with the greatest toenail involvement at baseline had greater overall improvements than those who were less affected. This evaluation provides additional clinical guidance for treating women with onychomycosis using tavaborole. J Drugs Dermatol. 2018;17(2):168-172.
View details for Web of Science ID 000424534100005
View details for PubMedID 29462224
- Neurogenic Rosacea: A Distinct Clinical Subtype Requiring a Modified Approach to Treatment ARCHIVES OF DERMATOLOGY 2011; 147 (1): 123-126